The following message was sent to you through the Alaska Public Health Alert Network (AK PHAN). Please share this information with others who may be interested.

Note: Contact information for the Alaska Section of Epidemiology can be found at the end of this message.

The Centers for Disease Control and Prevention (CDC) has issued a health advisory regarding the use of LeadCare® analyzers (LeadCare®, LeadCare® II, LeadCare® Ultra and LeadCare® Plus). This safety alert applies only to venous draws that are analyzed with the LeadCare® analyzers; it does not apply to capillary blood lead test results collected by fingerstick or heelstick using LeadCare® analyzers. Since the Alaska State Public Health Laboratory (ASPHL) only uses ICP-MS for lead testing, not LeadCare®, data previously reported by ASPHL for whole blood and capillary blood lead are not being called into question by this alert.

**This is an official**

**CDC HEALTH ADVISORY**

Distributed via the CDC Health Alert Network
May 17, 2017, 0900 ET (9:00 AM ET)
CDCHAN-00403

**Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers**

**Summary**
The U.S. Food and Drug Administration (FDA) has issued a safety communication warning about the use of Magellan Diagnostics’ LeadCare® analyzers (LeadCare, LeadCare II, LeadCare Ultra and LeadCare Plus) with venous blood samples because they might result in falsely low test results. FDA is now advising that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples. The safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick. The purpose of this Health Advisory is to notify state and local health departments, healthcare providers, and laboratories about CDC’s re-testing guidance in light of the safety alert.

**Background**
CDC was contacted on April 24, 2017 by FDA requesting assistance in assessing the potential public health risk of a negative bias associated with Magellan’s lead testing systems. FDA is now warning that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples due to the potential for falsely low test results. Not all blood lead tests are affected. Laboratory tests analyzed by inductively coupled plasma-mass spectrometry (ICP-MS) or graphite furnace atomic spectrometry (GFAAS) (also known as electrothermal atomic absorption spectrometry [ETAAS]) are not expected to have resulted in falsely low results. **This safety alert applies to venous blood lead tests conducted using Magellan Diagnostics’ LeadCare® analyzers whether the patient is a child or an adult. At this time, the safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick using Magellan Diagnostics’ LeadCare® analyzers.** Children are particularly vulnerable to lead exposure due to the effect on their developing brains and organ systems. CDC is working with public health officials throughout the United States to determine where the analyzers were used and which blood lead test results might be affected.
Recommendations

CDC recommends that healthcare providers re-test patients who:

1) are younger than 6 years (72 months) of age at the time of the alert (May 17, 2017) and
2) had a venous blood lead test result of less than 10 micrograms per deciliter (µg/dL) analyzed using a Magellan Diagnostics' LeadCare® analyzer at an onsite (e.g., healthcare facility) or at an offsite laboratory.

CDC also recommends that healthcare providers re-test currently pregnant or lactating women who had a venous blood lead test performed using a Magellan Diagnostics' LeadCare® analyzer.

CDC recommends parents discuss re-testing with their healthcare provider or health department to determine if their child's blood should be re-tested.

If re-testing indicates blood lead levels in excess of the CDC reference level (www.cdc.gov/nceh/lead/acclpp/blood_lead_levels.htm), or the state or local action level, the healthcare provider or public health official should refer to CDC and/or local guidelines for appropriate follow-up action (www.cdc.gov/nceh/lead/acclpp/actions_blls.html).

Re-tests are not recommended if the provider is certain that analyzers other than those described by this Health Advisory were used to analyze the venous blood samples.

For future blood lead testing, healthcare providers and public health officials should:

- Send venous samples to Clinical Laboratory Improvement Amendments (CLIA)-compliant laboratories using inductively coupled plasma mass spectrometry (ICP-MS) or graphite furnace atomic absorption spectrometry (GFAAS) (also known as electrothermal atomic absorption spectrometry [ETAAS]) instruments.
- Send capillary samples to CLIA-compliant laboratories using any CLIA compliant analyzer including ICP-MS, GFAAS, or LeadCare® analyzers.

For More Information

CDC’s Lead Poisoning Prevention Program: https://www.cdc.gov/nceh/lead/

CDC’s Lead and Multi-element Proficiency Program: https://www.cdc.gov/labstandards/lamp.html

Reference

FDA safety communication warning, May 17, 2017. Available at: https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm558733.htm

The Centers for Disease Control and Prevention (CDC) protects people’s health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.

Categories of Health Alert Network messages:

- **Health Alert**: Requires immediate action or attention; highest level of importance
- **Health Advisory**: May not require immediate action; provides important information for a specific incident or situation
- **Health Update**: Unlikely to require immediate action; provides updated information regarding an incident or situation
- **HAN Info Service**: Does not require immediate action; provides general public health information